ArticleMycopathologia2025
Character Virulence Association Factors and Gene Mutation Mediating Multidrug Resistance Phenotypes in Candidozyma duobushaemulonii.
Article in Mycopathologia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Comparative Analysis of Virulence Traits and Fluconazole-Response Mechanisms in Clinical Isolates ofMicroorganisms · 2026Article
- Phylogenetic Profiling of the Diabetic Foot Ulcer Microbiome of an Afro-Caribbean Population.MicrobiologyOpen · 2026Article
- Silent Outbreaks ofAntibiotics (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Candidiasis, traditionally dominated by Candida albicans infection, now faces a paradigm shift with the emergence of non-C. albicans infections, such as the multidrug-resistant (MDR) Candidozyma (formerly Candida) species. Critically, the emergence of multidrug resistance (MDR) Candidozyma duobushaemulonii (also known as Candida duobushaemulonii) poses critical challenges to antifungal therapy. Here, in this comparative study, we analyzed four clinical C. duobushaemulonii isolates (cd, cd1, cd2, and cd3) to establish strain-specific virulence and antifungal resistance profiles. Biofilm quantification using crystal violet (CV) and 2,3-Bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide (XTT) metabolic activity assays showed different biomass production levels across strains. Cellular aggregation capacity differed significantly, while cell surface hydrophobicity (CSH) showed inverse patterns. In Galleria mellonella infection models, virulence stratification was observed. Antifungal susceptibility testing revealed minimum inhibitory concentration (MIC) azole gradients. MDR in the cd1 strain extended to 5-fluorocytosine (5-FC) and anidulafungin (ANI), whereas the cd3 strain showed intermediate posaconazole (PSZ) resistance distinct to the cd2 strain. Amino acid sequence analyses indicated that Y132F substitutes in ERG11 and D139N in FUR1 genes occurred in cd and cd1 strains. Gene expression analysis recorded various regulatory situations among strains. These analyses provide a complete resistance-virulence matrix for C. duobushaemulonii, establishing baseline characteristics for epidemiological surveillance and a reference framework for future comparative studies.
Indexed as
Identifiers
41042413What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.